Oncolytics Biotech Inc.ONCY

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · oncolyticsbiotech.com

Oncolytics Biotech Inc. is a Calgary-based biopharmaceutical company developing pelareorep, an intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. Pelareorep induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses, turning cold tumors hot to enhance anti-cancer immunity. The company's lead programs include registration-enabling studies in metastatic breast cancer and pancreatic cancer, with the drug also trading on NASDAQ under the symbol ONCY.

Key ratios

ROA

-161.0%TTM

2025 -161.0%2024 -74.1%2023 -55.5%

ROE

-10187.6%TTM

2025 -10187.6%2024 -189.1%2023 -102.7%

Recent news

Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer 2026-09-10 · GlobeNewswire Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer 2026-07-20 · GlobeNewswire Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 2026-06-16 · GlobeNewswire Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer 2026-06-02 · GlobeNewswire Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors 2026-05-22 · GlobeNewswire

Track ONCY in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer